Second Chakra (Sacral) 7302
NDC 63083-7302, Second Chakra (Sacral), liquid, from Professional Complementary Health Formulas.
- Product NDC
- 63083-7302
- Status
- Listed
- Labeler
- Professional Complementary Health Formulas
- Dosage form
- LIQUID
- Route
- ORAL
- Product type
- HUMAN OTC DRUG
- Marketing category
- UNAPPROVED HOMEOPATHIC
- Application
- —
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/63083-7302 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- HELLEBORUS NIGER ROOT8 [hp_X]/29.5mL
- STRYCHNOS IGNATII SEED8 [hp_X]/29.5mL
- POTASSIUM CHLORATE8 [hp_X]/29.5mL
- MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE8 [hp_X]/29.5mL
- ARTEMISIA CINA PRE-FLOWERING TOP10 [hp_X]/29.5mL
- BOS TAURUS BILE12 [hp_X]/29.5mL
- LACHESIS MUTA VENOM12 [hp_X]/29.5mL
- SEPIA OFFICINALIS JUICE12 [hp_X]/29.5mL
- SILICON DIOXIDE30 [hp_X]/29.5mL
Pharmacologic classes
Calculi Dissolution Agent [EPC]; Increased Large Intestinal Motility [PE]; Increased Large Intestinal Motility [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Inhibition Small Intestine Fluid/Electrolyte Absorption [PE]; Magnesium Ion Exchange Activity [MoA]; Osmotic Activity [MoA]; Osmotic Activity [MoA]; Osmotic Laxative [EPC]; Osmotic Laxative [EPC]; Potassium Compounds [CS]; Potassium Salt [EPC]; Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 63083-7302-1 | 63083730201 | 29.5 mL in 1 BOTTLE, DROPPER (63083-7302-1) |
Linked data
RxNorm, label and prices
RxNorm concepts
RxNorm links no concept to this product's packages.
Related lookups
No FDA label, Medicare Part B payment limit or NADAC price is linked to this product.
Use it
Look up 63083-7302 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/63083-7302 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 63083-7302. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.